In a clinical study in children with new-onset T1D, etanercept, a fusion protein that binds TNF and blocks its activity, led to a reduction in haemoglobin A1c (HbA1c) and improved endogenous insulin responses157. This evidence concerns the gene INS and type 1 diabetes mellitus.